David Burgoyne, Ph.D., President

Dr. David Burgoyne, Founder and President of Naegis Pharmaceuticals, has over 20 years experience in the business of drug discovery and early stage pharmaceutical development. Trained as a marine natural products chemist, David obtained his Ph.D. from the University of British Columbia in 1992 for his studies on Pacific Ocean marine sponges. This research led to the discovery of Contignasterol, a marine natural product with anti-inflammatory properties which formed the basis of the LSAID platform technology for Inflazyme Pharmaceuticals Ltd. For this and subsequent research, he was awarded the Science Council of BC Young Innovator award in 2000. At Inflazyme David held executive positions as VP Research, serving as a key contributor to teams which advanced multiple products from discovery to clinical development, and VP Business Development, where his experience included licensing, mergers and acquisitions. David founded Naegis in 2009 recognizing that serious inflammatory diseases in our aging population remain a critical health problem in need of novel solutions.

John Langlands, Ph.D., Vice President Pre-Clinical Research

Joining Naegis in the summer of 2013, Dr. John Langlands brings over 20 years experience in the development of new pharmaceuticals. John obtained his Ph.D. in pharmacology from the University of Strathclyde and has extensive experience in inflammatory diseases, in particular respiratory and allergic conditions. He has worked with several early stage biopharmaceutical companies with a focus on preclinical regulatory strategies and early clinical development programs required to obtain proof of value for future project development. He has also been involved in strategic planning and translation of discovery concepts to clinical application, and implementation of quality management programs in various regulatory and clinical settings. Using his wide breadth of experience in drug development, John was the Program Authority and Senior Lecturer for postgraduate training in Pharmaceutical Medicine & Drug Development for several years at UNSW in Sydney, Australia and prior to that held senior roles in preclinical and clinical research at Inflazyme Pharmaceuticals.

Vincent Duronio, Ph.D., Research Biology

Dr. Duronio is a key collaborator with Naegis in research biology and has served as an advisor to the company since its inception. He obtained his Ph.D. in Biochemistry at the University of Western Ontario. Following his thesis on the regulation of glucose uptake in muscle cells, he pursued a post-doctoral fellowship with Drs. Pedro Cuatrecasas and Steven Jacobs at the Wellcome Research Laboratories in Research Triangle Park, NC, investigating mechanisms of signal transduction via insulin and insulin-like growth factor receptors. His next appointment was at the Biomedical Research Centre at UBC, focusing on the newly emerging family of cytokine receptors in relation to signal transduction pathways. He is currently a full professor with the Respiratory Division of the UBC Dept. of Medicine and continues his research involving the regulation of inflammatory cells.

Dr. Duronio has over 100 publications and has been awarded grants from various agencies, most notably the Canadian Institutes for Health Research, the Heart and Stroke Foundation, National Cancer Institute, BC Lung Association and the Cancer Research Society. Dr. Duronio was among the first group awarded a Senior Scholar award by The Michael Smith Foundation for Health Research. He has also been on numerous grant review panels for each of these agencies, as well as others. His most recent administrative role has been as the director of the UBC Experimental Medicine Graduate Program, overseeing the progress of 200 M.Sc. and Ph.D. students.